TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Brief Summary: Delirium is associated with increased risk of death, prolonged stay, higher cost of care, and likely long-term brain deficits in survivors. This form of brain dysfunction occurs in intensive care unit (ICU) patients in epidemic proportions, and the scope of this problem is likely to worsen in upcoming years due to the aging of our population and increased utilization of the ICU. Currently, delirium goes unrecognized and untreated in the vast majority of circumstances in the ICU unless the patient presents with hyperactive delirium and agitation. In the latter circumstance, a commonly used typical antipsychotic called haloperidol is considered the principal agent for treating delirium based largely on anecdotal evidence to support its usefulness, though no placebo controlled trials exist. There are no FDA approved medications for delirium. The atypical antipsychotics provide a promising alternative for the treatment of delirium due to their enhanced beneficial effects on positive (agitated) and negative (quiet) symptoms proven in mania and schizophrenia, reduced risk for side effects common to haloperidol such as extrapyramidal symptomatology, and less potentially lethal heart rhythm disturbances. It is imperative that well-designed phase II studies to determine proof of principle be conducted. A pilot study of feasibility to begin assessing the role of antipsychotics in the management of ICU delirium.


Options:
A: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): haloperidol
B: Arm Label: A - placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): A - placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2
D: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.
Brief Summary: The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, remember, judge, and reason) functioning in subjects with stable Bipolar I Disorder.


Options:
A: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone
B: Intervention Type: DRUG; Name: risperidone; quetiapine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine, risperidone | Intervention Type: DRUG; Name: quetiapine, risperidone; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Estrogen Use in Protection From Cognitive Decline
Brief Summary: This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2
D: Intervention Type: DRUG; Name: Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Insulin Aspart Versus Insulin Lispro in Insulin Pumps in Children and Adolescents With Type 1 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.


Options:
A: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: biphasic insulin aspart; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: insulin lispro; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil
Brief Summary: The perinatal morbidity and mortality rates for Brazil are five to ten-fold higher than those reported for upper income countries. This study tests the likelihood that the joint administration of antioxidants vitamin C (1000 mg) and vitamin E (400 IU) will reduce the incidence of preeclampsia among chronically hypertensive pregnant patients and patients with a past history of preeclampsia/eclampsia.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Arm Label: 400 micrograms of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Arm Label: 4mg of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Intervention Type: DRUG; Name: Folic acid: 4 mg versus 0.4 mg per day; Assigned to Arm(s): 400 micrograms of folic acid, 4mg of folic acid
C: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA
D: Intervention Type: DRUG; Name: Vitamin C and E; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Misoprostol for Postpartum Hemorrhage in India
Brief Summary: Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
B: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Misoprostol for Postpartum Hemorrhage in India
Brief Summary: Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
B: Arm Label: Saline group; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Saline group
C: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3
D: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Misoprostol for Postpartum Hemorrhage in India
Brief Summary: Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.


Options:
A: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A
D: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis
Brief Summary: This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.


Options:
A: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Cohort; Type: N/A; Interventions: Biological: Rituximab | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Cohort
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis
Brief Summary: This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1
C: Arm Label: MabThera/Rituxan; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): MabThera/Rituxan | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): MabThera/Rituxan
D: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis
Brief Summary: This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.


Options:
A: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
B: Arm Label: RNF 44 mcg three times weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo twice weekly for blinding; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo three times weekly; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo three times weekly, RNF 44 mcg once weekly and placebo twice weekly for blinding
C: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg
D: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder
Brief Summary: The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.


Options:
A: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C

Answer: D